vs

Side-by-side financial comparison of Empire State Realty Trust, Inc. (ESRT) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

Empire State Realty Trust, Inc. is the larger business by last-quarter revenue ($190.3M vs $186.7M, roughly 1.0× NEOGENOMICS INC). Empire State Realty Trust, Inc. runs the higher net margin — 1.6% vs -57.9%, a 59.4% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs 5.7%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs 0.2%).

Empire State Realty Trust is a leading real estate investment trust that owns, manages, and operates a portfolio of premium commercial, residential, and retail properties primarily in the New York City metropolitan area, including the iconic Empire State Building. It serves corporate tenants, retail partners, and residential occupants, focusing on sustainable property operations and long-term asset value growth.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

ESRT vs NEO — Head-to-Head

Bigger by revenue
ESRT
ESRT
1.0× larger
ESRT
$190.3M
$186.7M
NEO
Growing faster (revenue YoY)
NEO
NEO
+5.4% gap
NEO
11.1%
5.7%
ESRT
Higher net margin
ESRT
ESRT
59.4% more per $
ESRT
1.6%
-57.9%
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
0.2%
ESRT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ESRT
ESRT
NEO
NEO
Revenue
$190.3M
$186.7M
Net Profit
$3.0M
$-108.0M
Gross Margin
43.3%
Operating Margin
15.5%
46.9%
Net Margin
1.6%
-57.9%
Revenue YoY
5.7%
11.1%
Net Profit YoY
-73.7%
42.0%
EPS (diluted)
$0.20
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESRT
ESRT
NEO
NEO
Q1 26
$190.3M
$186.7M
Q4 25
$199.2M
$190.2M
Q3 25
$197.7M
$187.8M
Q2 25
$191.3M
$181.3M
Q1 25
$180.1M
$168.0M
Q4 24
$197.6M
$172.0M
Q3 24
$199.6M
$167.8M
Q2 24
$189.5M
$164.5M
Net Profit
ESRT
ESRT
NEO
NEO
Q1 26
$3.0M
$-108.0M
Q4 25
$32.2M
Q3 25
$13.6M
$-27.1M
Q2 25
$11.4M
$-45.1M
Q1 25
$15.8M
$-25.9M
Q4 24
$18.8M
Q3 24
$22.8M
$-17.7M
Q2 24
$28.6M
$-18.6M
Gross Margin
ESRT
ESRT
NEO
NEO
Q1 26
43.3%
Q4 25
43.8%
Q3 25
42.8%
Q2 25
42.6%
Q1 25
43.6%
Q4 24
44.9%
Q3 24
44.6%
Q2 24
44.1%
Operating Margin
ESRT
ESRT
NEO
NEO
Q1 26
15.5%
46.9%
Q4 25
17.8%
-7.1%
Q3 25
19.9%
-14.4%
Q2 25
18.4%
-26.3%
Q1 25
14.3%
-16.6%
Q4 24
21.7%
-10.7%
Q3 24
22.7%
-12.6%
Q2 24
20.8%
-13.3%
Net Margin
ESRT
ESRT
NEO
NEO
Q1 26
1.6%
-57.9%
Q4 25
16.1%
Q3 25
6.9%
-14.4%
Q2 25
6.0%
-24.9%
Q1 25
8.8%
-15.4%
Q4 24
9.5%
Q3 24
11.4%
-10.5%
Q2 24
15.1%
-11.3%
EPS (diluted)
ESRT
ESRT
NEO
NEO
Q1 26
$0.20
$-0.13
Q4 25
$0.11
Q3 25
$0.05
Q2 25
$0.04
Q1 25
$0.05
Q4 24
$0.07
Q3 24
$0.08
Q2 24
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESRT
ESRT
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$68.8M
$146.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.8B
$828.8M
Total Assets
$4.4B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESRT
ESRT
NEO
NEO
Q1 26
$68.8M
$146.1M
Q4 25
$132.7M
$159.6M
Q3 25
$154.1M
$164.1M
Q2 25
$94.6M
$154.7M
Q1 25
$187.8M
$346.2M
Q4 24
$385.5M
$367.0M
Q3 24
$421.9M
$362.0M
Q2 24
$535.5M
$355.1M
Total Debt
ESRT
ESRT
NEO
NEO
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
Q3 24
Q2 24
Stockholders' Equity
ESRT
ESRT
NEO
NEO
Q1 26
$1.8B
$828.8M
Q4 25
$1.1B
$836.6M
Q3 25
$1.0B
$838.3M
Q2 25
$1.0B
$854.0M
Q1 25
$1.0B
$888.3M
Q4 24
$1.0B
$902.3M
Q3 24
$1.0B
$908.2M
Q2 24
$1.0B
$915.9M
Total Assets
ESRT
ESRT
NEO
NEO
Q1 26
$4.4B
$1.3B
Q4 25
$4.5B
$1.4B
Q3 25
$4.1B
$1.4B
Q2 25
$4.1B
$1.4B
Q1 25
$4.1B
$1.6B
Q4 24
$4.5B
$1.6B
Q3 24
$4.4B
$1.6B
Q2 24
$4.4B
$1.6B
Debt / Equity
ESRT
ESRT
NEO
NEO
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESRT
ESRT
NEO
NEO
Operating Cash FlowLast quarter
$-8.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
10.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESRT
ESRT
NEO
NEO
Q1 26
$-8.1M
Q4 25
$249.1M
$1.3M
Q3 25
$105.3M
$8.9M
Q2 25
$26.7M
$20.3M
Q1 25
$83.1M
$-25.3M
Q4 24
$260.9M
$9.8M
Q3 24
$102.8M
$9.2M
Q2 24
$37.1M
$13.9M
Free Cash Flow
ESRT
ESRT
NEO
NEO
Q1 26
Q4 25
$50.6M
$-6.5M
Q3 25
$72.8M
$570.0K
Q2 25
$-55.1M
$14.0M
Q1 25
$41.1M
$-29.8M
Q4 24
$88.0M
$-1.8M
Q3 24
$-65.1M
$-1.6M
Q2 24
$19.5M
$814.0K
FCF Margin
ESRT
ESRT
NEO
NEO
Q1 26
Q4 25
25.4%
-3.4%
Q3 25
36.8%
0.3%
Q2 25
-28.8%
7.7%
Q1 25
22.8%
-17.8%
Q4 24
44.5%
-1.0%
Q3 24
-32.6%
-0.9%
Q2 24
10.3%
0.5%
Capex Intensity
ESRT
ESRT
NEO
NEO
Q1 26
10.0%
Q4 25
99.6%
4.1%
Q3 25
16.5%
4.4%
Q2 25
42.8%
3.5%
Q1 25
23.4%
2.7%
Q4 24
87.5%
6.7%
Q3 24
84.1%
6.4%
Q2 24
9.3%
8.0%
Cash Conversion
ESRT
ESRT
NEO
NEO
Q1 26
Q4 25
7.74×
Q3 25
7.72×
Q2 25
2.35×
Q1 25
5.27×
Q4 24
13.88×
Q3 24
4.51×
Q2 24
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESRT
ESRT

Rental revenue (1)$166.1M87%
Observatory revenue$18.5M10%
Other revenue and fees$4.1M2%
Lease termination fees$1.4M1%
Third-party management and other fees$277.0K0%

NEO
NEO

Segment breakdown not available.

Related Comparisons